What Codeine Phosphate 10% Shionogi Treats: Main Uses and Benefits

Relief for Mild to Moderate Acute Pain

This preparation is commonly used to help with symptoms related to physical discomfort that fall within the mild to moderate range of intensity, such as discomfort from minor injuries, myalgia, or pain following dental procedures. This class of agents may assist with managing the burden of pain. Its primary benefit is to alleviate discomfort, which may assist with maintaining functional stability when symptoms interfere with routine activities and additional symptomatic support is needed.

---

Suppression of Persistent, Non-Productive Cough

The medication is applied in addressing contexts where a persistent or troublesome dry cough is causing noticeable physiological strain. It is used for managing the symptoms related to inflammatory or irritative states by supporting the control of the cough reflex. This contributes to easing the overall symptom load, and may assist with maintaining a sense of stability and comfort, particularly when symptoms related to heightened physiological activity (cough) interfere with daily functioning, such as rest.

---

Use in Symptom-Driven Clinical Contexts

The liquid formulation is relevant in clinical settings where symptoms are episodic and short-term symptomatic assistance is needed. It is commonly used when symptoms intensify temporarily and become difficult to tolerate, supporting patients through phases of increased discomfort or tension where short-term relief is appropriate. The liquid dosage form may assist with administration in situations where patients experience difficulty swallowing.

Indications Summary: The relevant therapeutic domains for this preparation generally include the symptomatic relief of mild to moderate pain and the suppression of a persistent, non-productive cough.

“The preparation is relevant for easing symptoms that interfere with daily functioning or create noticeable physiological strain.”

Quick Fact: Relief for Acute Symptoms This medication is often applied in scenarios requiring additional management of discomfort or cough, particularly when symptoms escalate temporarily and interfere with daily functioning or rest.

Regulatory References

1. NIH MedlinePlus overview on Codeine

Eligibility Map: Who can and cannot use Codeine Phosphate 10% Shionogi

The eligibility for Codeine Phosphate 10% Shionogi is strictly defined by regulatory authorities based on age, metabolism, and pre-existing conditions.

Absolute Contraindications

Use is contraindicated (must not be used) in the following groups:

• Children younger than 12 years of age for any indication.
• All pediatric patients (0-18 years) following tonsillectomy and/or adenoidectomy for Obstructive Sleep Apnoea Syndrome (OSA).
• Patients known to be CYP2D6 ultra-rapid metabolisers (due to the risk of opioid toxicity).
• Women during breastfeeding.
• Patients with significant respiratory depression, severe hepatic dysfunction, or gastrointestinal obstruction (e.g., paralytic ileus).

Restricted or Conditional Use

Use is not recommended for adolescents aged 12 to 18 years who have compromised respiratory function.

Use requires caution or reduced doses for patients with renal impairment, hepatic impairment, or who are elderly/debilitated. The label also notes that regular use during pregnancy may lead to neonatal opioid withdrawal syndrome.

Interactions with other medicines and products

Codeine's interaction profile is categorized by its effects on drug metabolism and additive effects on the central nervous system (CNS).

Pharmacokinetic Interactions (Drug Metabolism)

• CYP2D6 Inhibitors: Co-administration with strong inhibitors, such as quinidine or amiodarone, may reduce the formation of codeine's active metabolite (morphine), potentially leading to a decrease in its expected effect.
• CYP3A4 Inducers: Substances that induce this enzyme may decrease codeine levels, while inhibitors may increase codeine levels, requiring careful observation.

Pharmacodynamic Interactions (Enhanced Effects)

• CNS Depressants: Concurrent use with drugs such as benzodiazepines, other opioids, alcohol, or sedatives can result in enhanced CNS depression, leading to severe outcomes including profound sedation and respiratory distress. Use of such combinations requires strict attention.
• Monoamine Oxidase Inhibitors (MAOIs): Concurrent use with MAOIs (or within 14 days of discontinuing them) is restricted due to the potential for greatly increased effects of the active metabolite, posing a high risk.
• Serotonergic Drugs: Co-administration with drugs affecting serotonin pathways may increase the risk of serotonin syndrome.
• Opioid Agonist/Antagonists: Combining codeine with mixed agonist/antagonist opioids (e.g., pentazocine) or partial agonist opioids (e.g., buprenorphine) is avoided as they may reduce the effect of codeine or precipitate withdrawal symptoms.

Codeine's Activation via CYP2D6 Enzyme

This drug works through an essential two-step mechanism, first acting as a prodrug that must be metabolized by the CYP2D6 enzyme in the liver to generate its primary active form, morphine. The rate of this enzymatic conversion influences the resulting concentration of the active metabolite, morphine, which mediates mu-Opioid Receptor (MOR) agonism, the principal mechanism mediating the modulation of nociceptive and cough reflex pathways.

---

mu-Opioid Receptor Agonism and Neural Signal Dampening

The active metabolites act as agonists on mu-Opioid Receptors, initiating a cellular cascade that inhibits neurotransmitter release and hyperpolarizes neurons in the central nervous system. This molecular action fundamentally dampens the transmission of nerve signals and reduces the excitability of the medullary cough center, which decreases the overall transmission of nociceptive signals.

---

Modulation of Gastrointestinal Motility

Beyond its central effects, the drug's mechanism also involves the agonism of mu-Opioid Receptors located in the enteric nervous system of the gastrointestinal tract. This action reduces propulsive peristalsis and increases smooth muscle tone, directly resulting in a slowed rate of gastrointestinal transit.

The use of Codeine Phosphate 10% Shionogi, an oral liquid preparation, is governed by specific protocols defining administration, dosing, frequency, and treatment duration. Dosing recommendations may vary; the following regimens describe standardized applications for this preparation.

Administration Scope

Instruction	Detail
Route of administration	The product is an Oral Solution intended for oral ingestion.
Dosing schedule (Adults)	Standard analgesic dosing ranges from 15 mg to 60 mg per dose. Antitussive dosing is typically 15 mg to 30 mg per dose. The maximum recommended daily dose for adults is generally 240 mg to 360 mg.
Timing in relation to meals	Administration may occur with or without food, as absorption is not significantly affected.
Preparation requirements	Measurement must be performed using an accurate, calibrated milliliter measuring device; household utensils should not be used for dose measurement.

---

Instruction Classifications and Procedural Structure

Classification	Detail
Frequency pattern	Dosing intervals are set at every 4 to 6 hours as needed, not to exceed 4 doses in a 24-hour period.
Age-group administration rules	The preparation is contraindicated in children younger than 12 years. Adolescents (12 to 18 years) receive weight-based dosing (0.5-1 mg/kg) with a daily maximum of 240 mg.
Special procedural conditions	The use of Codeine is limited to 3 days for acute pain relief. Treatment protocols mandate the use of the lowest effective dosage for the shortest duration. Dose reduction is necessary for older adults and patients with known renal or hepatic impairment.

---

Connection to the overall use protocol (3 sentences):

These standardized instructions establish a protocol by defining the oral route, the required 4-to-6-hour minimum dosing interval, and a strict 3-day limitation for acute applications. The framework mandates precise mg ranges for specific indications and requires dose adjustments for vulnerable populations, ensuring administration adheres to established parameters. The overall structure is centered on short-term, symptom-driven application.

Recent Clinical Evidence: Codeine Phosphate

This overview summarizes the research surrounding the use of codeine phosphate within clinical settings. Codeine is a commonly investigated opioid analgesic that acts centrally to manage pain, often studied in formulations like the one produced by Shionogi.

---

Phase III Randomized Controlled Trials (RCTs)

The primary evidence base for codeine's efficacy typically involves comparative Phase III RCTs. These studies often compare the analgesic effects of codeine, alone or in combination, against placebo or non-opioid alternatives in populations experiencing moderate pain, such as post-surgical pain or chronic non-malignant pain.

• Efficacy Investigations: Trials evaluate the compound's effect on primary outcomes such as pain intensity scores (e.g., using a Visual Analog Scale or VAS) and the proportion of participants achieving meaningful pain relief within a set timeframe. Findings generally confirm the compound's analgesic activity across studied pain models.

---

Safety and Long-Term Data

Clinical research consistently addresses the established safety profile of codeine, focusing on common and expected adverse effects associated with opioid use.

Area of Research	Focus of Investigation
Tolerability	Studies monitor common adverse events, including nausea, vomiting, constipation, and drowsiness.
Long-Term Data	Research tracks the incidence of dependency, tolerance, and withdrawal symptoms in extended-use scenarios.

Limitations in Current Research

Current evidence acknowledges the variability in patient response due to the metabolic pathway of codeine (specifically, conversion to morphine by the CYP2D6 enzyme). Research continues to explore the impact of individual genetic variation on both analgesic efficacy and the occurrence of adverse events.

Common questions about Codeine Phosphate 10% Shionogi (FAQ)

Q: What is the main substance in Codeine Phosphate 10% Shionogi?

The main active substance in this medication is codeine phosphate. Regulatory documents define this product as a prescription-only pharmaceutical preparation intended for oral ingestion.

---

Q: Is Codeine Phosphate 10% Shionogi the same as regular codeine?

Official documents describe Codeine Phosphate 10% Shionogi as a specific, prescription-only liquid formulation. Its active component is codeine phosphate, which is classified pharmacologically as a semi-synthetic opioid alkaloid.

---

Q: How quickly can Codeine Phosphate 10% Shionogi start working?

Official guidance does not provide a specific onset time. However, the dosing frequency is established at intervals of every four to six hours, which is consistent with the established parameters for its use.

---

Q: How long does the effect of Codeine Phosphate 10% Shionogi usually last?

The recommended dosing interval, which is typically set at every four to six hours, is the established standard for its use. Official instructions govern this frequency based on required symptom management.

---

Q: Are there any major food or drink restrictions with Codeine Phosphate 10% Shionogi?

Regulatory documents advise that alcohol should be avoided during the use of this medicine due to the risk of enhanced central nervous system (CNS) depression. Regarding food, administration is generally described as permissible with or without food, as absorption is not significantly affected.

---

Q: Is it okay to take Codeine Phosphate 10% Shionogi with paracetamol (acetaminophen)?

Some regulatory documents describe combination products that contain both codeine and acetaminophen. When taken together, official warnings note that attention is required due to the potential for serious adverse effects and the necessity of ensuring proper dosage levels for both active components.

---

Q: Does this medicine interact with common cold or flu remedies?

Official interaction warnings note a potential for enhanced effects when taken with certain cold, flu, or allergy remedies. This is specifically linked to remedies that contain CNS depressants or antihistamines, which may increase effects like drowsiness or dizziness.

---

Q: Does Codeine Phosphate 10% Shionogi interact with antidepressants?

Concurrent use of this medicine with certain types of antidepressants is noted to carry a risk of developing serotonin syndrome. This risk is associated with drugs that affect the body's serotonin pathways.

---

Q: Is Codeine Phosphate 10% Shionogi safe for elderly patients?

Regulatory protocols for use in elderly patients indicate that caution is required. Official administration instructions also indicate that a reduction in the prescribed dose may be considered for older adults.

---

Q: Can this medicine affect my ability to drive or operate machinery?

Official information cautions that the medicine may cause effects such as drowsiness, dizziness, or confusion. Due to these potential central nervous system effects, regulatory warnings indicate that driving or operating machinery should be avoided until a person is aware of how the medicine affects them.

---

Q: Is Codeine Phosphate 10% Shionogi a controlled substance?

Yes, the active ingredient, codeine, is classified as a controlled drug by federal agencies. The specific schedule designation (e.g., Schedule II, III, or V) can vary based on the drug's formulation and concentration.

---

Q: What does the research evidence say about the use of codeine phosphate for cough suppression?

Official pharmacological classification defines this medicine as an antitussive, meaning it is intended to suppress coughs. While clinical studies often evaluate its effectiveness for pain relief, its use for cough is grounded in its official designation as a centrally acting cough-suppressing agent.

---

Q: Can Codeine Phosphate 10% Shionogi cause allergic reactions?

Regulatory safety information notes that allergic reactions are a potential serious side effect. These reactions may be described as symptoms such as a rash, hives, swelling, or difficulty breathing.

---

Q: Does Codeine Phosphate 10% Shionogi affect blood pressure?

Official safety information indicates that low blood pressure, or hypotension, is a possible adverse effect. This is a symptom that is monitored during the use of opioid medications.

---

Q: What is drug dependence in the context of codeine use?

Drug dependence and tolerance are serious adverse reactions associated with extended use. Official sources describe this as a risk that may involve finding it difficult to stop using the medication or requiring progressively higher amounts to achieve the same effect.

---

Q: Can Codeine Phosphate 10% Shionogi interact with herbal supplements?

Regulatory information notes that potential interactions exist with certain nonprescription and herbal products. For example, some regulatory safety sheets specifically mention potential interactions with St. John’s wort.

---

Q: Is it common to feel restless when taking Codeine Phosphate 10% Shionogi?

Restlessness is not typically listed among the most common adverse reactions. However, regulatory guidance notes that it may occur in situations where the prescribed dose fails to relieve pain, or as a potential symptom of withdrawal.

---

Q: What conditions make a person a poor metabolizer of codeine?

The way the body processes codeine relies on the CYP2D6 enzyme, which can vary genetically from person to person. Official information notes that genetic variations in this enzyme can lead to a reduced formation of the active drug component.

---

Q: Can Codeine Phosphate 10% Shionogi affect my mood?

The medicine works in the central nervous system to reduce the transmission of pain signals. As part of this action, official descriptions note that it can also help to reduce the associated anxiety and stress caused by pain.

---

Q: What should be avoided while using Codeine Phosphate 10% Shionogi?

Regulatory documents indicate that alcohol, other CNS depressants, and certain MAOI medications should be avoided. The labeling also notes that the medicine should not be used while breastfeeding or when operating machinery if affected by drowsiness.

---

Q: Can Codeine Phosphate 10% Shionogi cause dry mouth?

Dry mouth is noted in official safety information as a possible side effect of this medicine.

---

Q: Does Codeine Phosphate 10% Shionogi carry a risk of overdose?

Yes, the use of this drug is accompanied by safety warnings regarding the risk of accidental overdose. This is categorized as a serious, life-threatening event that is addressed in regulatory safety information.

The storage and disposal of Codeine Phosphate Oral Solution are strictly defined by regulatory authorities to maintain product integrity and prevent risks associated with this opioid.

Storage Requirement	Official Regulatory Mandate
Temperature	Store at controlled room temperature (20^circ to 25 C or 68^circ to 77 F) [FDA/USP].
Protection	Protect from light and do not freeze [SmPC/National Data Sheets].
Container	Must be kept tightly closed in the original container with a child-resistant closure [FDA/MHRA].
Child Safety	Store out of the sight and reach of children due to the risk of accidental overdose [Universal Mandate].
Disposal	Dispose of unused product via an official drug take-back program (preferred) [FDA Guidance]. Do not flush down the toilet unless explicitly instructed to do so on the label.